Compare ETR & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ETR | BDX |
|---|---|---|
| Founded | 1949 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.4B | 51.5B |
| IPO Year | 2005 | 1995 |
| Metric | ETR | BDX |
|---|---|---|
| Price | $115.67 | $155.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 13 |
| Target Price | $111.13 | ★ $186.92 |
| AVG Volume (30 Days) | ★ 2.6M | 2.0M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | 2.22% | ★ 2.70% |
| EPS Growth | ★ 59.59 | N/A |
| EPS | ★ 3.91 | 1.34 |
| Revenue | $12,946,686,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $8.28 | N/A |
| Revenue Next Year | $8.14 | $2.22 |
| P/E Ratio | ★ $29.48 | $115.95 |
| Revenue Growth | ★ 8.98 | 8.24 |
| 52 Week Low | $79.48 | $152.79 |
| 52 Week High | $117.81 | $213.08 |
| Indicator | ETR | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 68.28 | 39.01 |
| Support Level | $91.91 | $153.75 |
| Resistance Level | N/A | $160.19 |
| Average True Range (ATR) | 2.35 | 3.02 |
| MACD | 0.48 | 1.05 |
| Stochastic Oscillator | 86.68 | 39.77 |
Entergy is a holding company with five regulated vertically integrated utilities that generate and distribute electricity to 3 million customers in Arkansas, Louisiana, Mississippi, and Texas. It is one of the largest power producers in the country with 27 gigawatts of rate-regulated owned and leased power generation capacity. Entergy was the second-largest nuclear owner in the US before it began retiring and selling its plants in the Northeast in 2014. It sold its two small gas utilities in Louisiana in 2025.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. On a 2025 sales basis, following the spinoff, BD Medical Essentials represented 34% of revenue, the Interventional segment 28%, Connected Care 25%, and Biopharma 13%. International revenue accounts for 43% of the company's business.